Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082212 | 1.00 | HTT (0.57) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL355825 | 1.00 | HTT (0.57) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1806126 | 0.90 | MAPT (0.55) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1809661 | 0.90 | MAPT (0.55) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11971460 | 0.90 | MAPT (0.55) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10458884 | 0.89 | MAPT (0.53) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18746297 | 0.89 | MAPT (0.53) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5969900 | 0.86 | MAPT (0.51) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL356454 | 0.86 | MAPT (0.51) | HTTMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL356453 | 0.86 | MAPT (0.51) | HTTMAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669070-A | Synthesis method of O- (dialkyl phosphinic group) ketoxime | 成都理工大学 | 2020-01-10 | — | — | CN | claimed |
| CN-110669070-B | Synthesis method of O- (dialkyl phosphinic group) ketoxime | 成都理工大学 | 2021-08-27 | — | — | CN | disclosed |
| CN-110669070-A | Synthesis method of O- (dialkyl phosphinic group) ketoxime | 成都理工大学 | 2020-01-10 | — | — | CN | disclosed |
| EP-3398452-A2 | COMESTIBLE COMPOSITIONS COMPRISING HIGH POTENCY SAVORY FLAVORANTS, AND PROCESSES FOR PRODUCING THEM | Senomyx, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3235811-B1 | PROCESS OF PREPARING OXALAMIDES | SENOMYX INC (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3235811-A1 | PROCESS OF PREPARING OXALAMIDES | Senomyx, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2010009-B1 | PROCESSES FOR PREPARING SOLID FLAVORANT COMPOSITIONS | SENOMYX INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9411226-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9411226-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | HTT 956/4885MAPT 2244/4885RAB9A 3006/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | HTT 956/4885MAPT 2244/4885RAB9A 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.